Tag Archives: Spinraza

Biogen’s poster presentation for Alzheimer’s candidate hardly noticed at London AAIC meeting as market focuses on quarterly results instead; start accumulating.

Biogen Inc. (Cambridge MA) laid out long-term plans to strengthen its core multiple sclerosis (MS) business, develop more neuroscience drugs and shop for late-stage assets, after reporting robust second-quarter results,… Read more »

CAR-T Therapy: Personalized medicine with the promise of a cure; payers will decide who gets it

The News: Swiss drug giant Novartis AG has drawn widespread praise and a rising dose of controversy pertaining to its breakthrough CAR-T therapy CTL019. The medicine is under review to… Read more »

Drugs that may shape 2017 and the trends molding new-drug discovery

Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »

Biotech predictions for 2017 return to positive fundamentals; 2016 meltdown still in rear-view mirror

The NASDAQ Biotech Index got hammered in 2016–-but mostly due to the market melting in January 2016. The Nasdaq Biotech Index collapsed 28% in the opening weeks of 2016 and… Read more »

New Biogen pick for CEO inherits tough job; markets aren’t exactly enthralled–yet

Biogen Inc. (Cambridge MA) said Monday (December 19, 2016) it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company’s commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this… Read more »